2018 Korean Guideline of Atrial Fibrillation Management

다국어 초록 (Multilingual Abstract)

Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia in the general population. The Korean Heart Rhythm Society organized a Korean AF Management Guideline Committee and analyzed all available studies regarding the management of AF, including studies on Korean patients. This guideline is based on recent data of the Korean population and the recent guidelines of the European Society of Cardiology, European Association for Cardio-Thoracic Surgery, American Heart Association, and Asia Pacific Heart Rhythm Society. Expert consensus or guidelines for the optimal management of Korean patients with AF were achieved after a systematic review with intensive discussion. This article provides general principles for appropriate risk stratification and selection of anticoagulation therapy in Korean patients with AF. This guideline deals with optimal stroke prevention, screening, rate and rhythm control, risk factor management, and integrated management of AF.

참고문헌 (Reference)

1 Gwag HB, "Which antiarrhythmic drug to choose after electrical cardioversion: a study on non-valvular atrial fibrillation patients" 13 : e0197352-, 2018

2 Mant J, "Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation(the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA) : a randomised controlled trial" 370 : 493-503, 2007

3 Chan KE, "Warfarin use associates with increased risk for stroke in hemodialysis patients with atrial fibrillation" 20 : 2223-2233, 2009

4 Hart RG, "Warfarin in atrial fibrillation patients with moderate chronic kidney disease" 6 : 2599-2604, 2011

5 Kowey PR, "Vernakalant hydrochloride for the rapid conversion of atrial fibrillation after cardiac surgery : a randomized, double-blind, placebo-controlled trial" 2 : 652-659, 2009

6 Roy D, "Vernakalant hydrochloride for rapid conversion of atrial fibrillation : a phase 3, randomized, placebo-controlled trial" 117 : 1518-1525, 2008

7 Hemels ME, "Verapamil versus digoxin and acute versus routine serial cardioversion for the improvement of rhythm control for persistent atrial fibrillation" 48 : 1001-1009, 2006

8 Yang PS, "Variations of prevalence and incidence of atrial fibrillation and oral anticoagulation rate according to different analysis approaches" 8 : 6856-, 2018

9 Alonso-Coello P, "Values and preferences in oral anticoagulation in patients with atrial fibrillation, physicians' and patients' perspectives : protocol for a two-phase study" 8 : 221-, 2008

10 Tomita H, "Validation of risk scoring system excluding female sex from CHA2DS2-VASc in Japanese patients with nonvalvular atrial fibrillation : subanalysis of the J-RHYTHM registry" 79 : 1719-1726, 2015

11 Guo Y, "Validation of contemporary stroke and bleeding risk stratification scores in non-anticoagulated Chinese patients with atrial fibrillation" 168 : 904-909, 2013

12 Badheka AO, "Utilization and adverse outcomes of percutaneous left atrial appendage closure for stroke prevention in atrial fibrillation in the United States : influence of hospital volume" 8 : 42-48, 2015

13 Chao TF, "Using the CHA2DS2-VASc score for refining stroke risk stratification in ‘low-risk’ Asian patients with atrial fibrillation" 64 : 1658-1665, 2014

14 Klein AL, "Use of transesophageal echocardiography to guide cardioversion in patients with atrial fibrillation" 344 : 1411-1420, 2001

15 Zulkifly H, "Use of the SAMe-TT2R2 score to predict anticoagulation control in atrial fibrillation and venous thromboembolism patients receiving vitamin K antagonists : a review" 15 : 615-623, 2018

16 Potpara TS, "Use of oral anticoagulants in patients with atrial fibrillation and renal dysfunction" 14 : 337-351, 2018

17 Madrid AH, "Use of irbesartan to maintain sinus rhythm in patients with long-lasting persistent atrial fibrillation : a prospective and randomized study" 106 : 331-336, 2002

18 Ueng KC, "Use of enalapril to facilitate sinus rhythm maintenance after external cardioversion of long-standing persistent atrial fibrillation. Results of a prospective and controlled study" 24 : 2090-2098, 2003

19 Dewilde WJ, "Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention : an open-label, randomised, controlled trial" 381 : 1107-1115, 2013

20 Heidbuchel H, "Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation" 17 : 1467-1507, 2015

21 Cappato R, "Uninterrupted rivaroxaban vs. uninterrupted vitamin K antagonists for catheter ablation in non-valvular atrial fibrillation" 36 : 1805-1811, 2015

22 Calkins H, "Uninterrupted dabigatran versus warfarin for ablation in atrial fibrillation" 376 : 1627-1636, 2017

23 Siontis KC, "Typical, atypical, and asymptomatic presentations of new-onset atrial fibrillation in the community : characteristics and prognostic implications" 13 : 1418-1424, 2016

24 Schoen T, "Type 2 diabetes mellitus and risk of incident atrial fibrillation in women" 60 : 1421-1428, 2012

25 Fangel MV, "Type 1 versus type 2 diabetes and thromboembolic risk in patients with atrial fibrillation : a Danish nationwide cohort study" 268 : 137-142, 2018

26 Aliot E, "Twenty-five years in the making : flecainide is safe and effective for the management of atrial fibrillation" 13 : 161-173, 2011

27 Lee SR, "Trends in the incidence and prevalence of atrial fibrillation and estimated thromboembolic risk using the CHA2DS2-VASc score in the entire Korean population" 236 : 226-231, 2017

28 Son MK, "Trend of prevalence of atrial fibrillation and use of oral anticoagulation therapy in patients with atrial fibrillation in South Korea(2002–2013)" 28 : 81-87, 2018

29 Mittal S, "Transthoracic cardioversion of atrial fibrillation : comparison of rectilinear biphasic versus damped sine wave monophasic shocks" 101 : 1282-1287, 2000

30 Hylek EM, "Translating the results of randomized trials into clinical practice : the challenge of warfarin candidacy among hospitalized elderly patients with atrial fibrillation" 37 : 1075-1080, 2006

31 Hansen ML, "Thromboembolic risk in 16 274 atrial fibrillation patients undergoing direct current cardioversion with and without oral anticoagulant therapy" 17 : 18-23, 2015

32 Olesen JB, "The value of the CHA2DS2-VASc score for refining stroke risk stratification in patients with atrial fibrillation with a CHADS2 score 0–1 : a nationwide cohort study" 107 : 1172-1179, 2012

33 Glotzer TV, "The relationship between daily atrial tachyarrhythmia burden from implantable device diagnostics and stroke risk : the TRENDS study" 2 : 474-480, 2009

34 Schwartzenberg S, "The quandary of oral anticoagulation in patients with atrial fibrillation and chronic kidney disease" 117 : 477-482, 2016

35 Rubboli A, "The optimal management of patients on oral anticoagulation undergoing coronary artery stenting. The 10th anniversary overview" 112 : 1080-1087, 2014

36 Jones C, "The management of atrial fibrillation: summary of updated NICE guidance" 348 : g3655-, 2014

37 Arbelo E, "The atrial fibrillation ablation pilot study : a European survey on methodology and results of catheter ablation for atrial fibrillation conducted by the European Heart Rhythm Association" 35 : 1466-1478, 2014

38 이한철, "The Trends of Atrial Fibrillation-Related Hospital Visit and Cost, Treatment Pattern and Mortality in Korea: 10-Year Nationwide Sample Cohort Data" 대한심장학회 47 (47): 56-64, 2017

39 Coppens M, "The CHA2DS2-VASc score identifies those patients with atrial fibrillation and a CHADS2 score of 1 who are unlikely to benefit from oral anticoagulant therapy" 34 : 170-176, 2013

40 Lip GY, "The ABC pathway : an integrated approach to improve AF management" 14 : 627-628, 2017

41 Steffel J, "The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation" 39 : 1330-1393, 2018

42 Lee SR, "Temporal trends of antithrombotic therapy for stroke prevention in Korean patients with non-valvular atrial fibrillation in the era of non-vitamin K antagonist oral anticoagulants : a nationwide population-based study" 12 : e0189495-, 2017

43 Brambatti M, "Temporal relationship between subclinical atrial fibrillation and embolic events" 129 : 2094-2099, 2014

44 Bash LD, "Systematic review and meta-analysis of the efficacy of cardioversion by vernakalant and comparators in patients with atrial fibrillation" 26 : 167-179, 2012

45 Saborido CM, "Systematic review and cost-effectiveness evaluation of ‘pill-in-the-pocket’ strategy for paroxysmal atrial fibrillation compared to episodic in-hospital treatment or continuous antiarrhythmic drug therapy" 14 : iii-iv, 2010

46 Singh SN, "Systematic electrocardioversion for atrial fibrillation and role of antiarrhythmic drugs : a substudy of the SAFE-T trial" 6 : 152-155, 2009

47 Healey JS, "Subclinical atrial fibrillation in older patients" 136 : 1276-1283, 2017

48 Healey JS, "Subclinical atrial fibrillation and the risk of stroke" 366 : 120-129, 2012

49 Eikelboom JW, "Stroke risk and efficacy of apixaban in atrial fibrillation patients with moderate chronic kidney disease" 21 : 429-435, 2012

50 Lip G, "Stroke prevention in atrial fibrillation : past, present and future. Comparing the guidelines and practical decision-making" 117 : 1230-1239, 2017

51 Freedman B, "Stroke prevention in atrial fibrillation" 388 : 806-817, 2016

52 Engdahl J, "Stepwise screening of atrial fibrillation in a 75-year-old population : implications for stroke prevention" 127 : 930-937, 2013

53 Kirchhof P, "Short-term versus long-term antiarrhythmic drug treatment after cardioversion of atrial fibrillation(Flec-SL) : a prospective, randomised, open-label, blinded endpoint assessment trial" 380 : 238-246, 2012

54 Seaburg L, "Shared decision making in atrial fibrillation : where we are and where we should be going" 129 : 704-710, 2014

55 Stiggelbout AM, "Shared decision making : really putting patients at the centre of healthcare" 344 : e256-, 2012

56 Avgil Tsadok M, "Sex differences in stroke risk among older patients with recently diagnosed atrial fibrillation" 307 : 1952-1958, 2012

57 Lorig KR, "Self-management education : history, definition, outcomes, and mechanisms" 26 : 1-7, 2003

58 Miyasaka Y, "Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence" 114 : 119-125, 2006

59 Lowres N, "Screening to identify unknown atrial fibrillation. A systematic review" 110 : 213-222, 2013

60 Freedman B, "Screening for atrial fibrillation : a report of the AF-SCREEN international collaboration" 135 : 1851-1867, 2017

61 Mairesse GH, "Screening for atrial fibrillation : a European Heart Rhythm Association(EHRA)consensus document endorsed by the Heart Rhythm Society(HRS), Asia Pacific Heart Rhythm Society(APHRS), and Sociedad Latinoamericana de Estimulación Cardíaca y Electrofisiología(SOLAECE)" 19 : 1589-1623, 2017

62 Kottmaier M, "Safety of uninterrupted periprocedural edoxaban versus phenprocoumon for patients who underwent left atrial catheter ablation procedures" 121 : 445-449, 2018

63 Chimienti M, "Safety of flecainide versus propafenone for the long-term management of symptomatic paroxysmal supraventricular tachyarrhythmias. Report from the Flecainide and Propafenone Italian Study (FAPIS) Group" 16 : 1943-1951, 1995

64 Scheuermeyer FX, "Safety and efficiency of calcium channel blockers versus beta-blockers for rate control in patients with atrial fibrillation and no acute underlying medical illness" 20 : 222-230, 2013

65 Stellbrink C, "Safety and efficacy of enoxaparin compared with unfractionated heparin and oral anticoagulants for prevention of thromboembolic complications in cardioversion of nonvalvular atrial fibrillation : the Anticoagulation in Cardioversion using Enoxaparin(ACE)trial" 109 : 997-1003, 2004

66 Golwala HB, "Safety and efficacy of dual vs. triple antithrombotic therapy in patients with atrial fibrillation following percutaneous coronary intervention: a systematic review and meta-analysis of randomized clinical trials" 39 : 1726-1735a, 2018

67 Hohnloser SH, "Safety and efficacy of dabigatran etexilate during catheter ablation of atrial fibrillation : a meta-analysis of the literature" 15 : 1407-1411, 2013

68 Furniss SS, "Safe sedation in modern cardiological practice" 101 : 1526-1530, 2015

69 Hori M, "Rivaroxaban vs. warfarin in Japanese patients with non-valvular atrial fibrillation in relation to age" 78 : 1349-1356, 2014

70 Cappato R, "Rivaroxaban vs. vitamin K antagonists for cardioversion in atrial fibrillation" 35 : 3346-3355, 2014

71 Patel MR, "Rivaroxaban versus warfarin in nonvalvular atrial fibrillation" 365 : 883-891, 2011

72 Du X, "Risks of cardiovascular events and effects of routine blood pressure lowering among patients with type 2 diabetes and atrial fibrillation : results of the ADVANCE study" 30 : 1128-1135, 2009

73 Siu CW, "Risk of stroke and intracranial hemorrhage in 9727 Chinese with atrial fibrillation in Hong Kong" 11 : 1401-1408, 2014

74 Kang SH, "Risk of ischemic stroke in patients with non-valvular atrial fibrillation not receiving oral anticoagulants : Korean nationwide population-based study" 81 : 1158-1164, 2017

75 Li Y, "Risk factors for new-onset atrial fibrillation : a focus on Asian populations" 261 : 92-98, 2018

76 Lin LY, "Risk factors and incidence of ischemic stroke in Taiwanese with nonvalvular atrial fibrillation--a nation wide database analysis" 217 : 292-295, 2011

77 Roy D, "Rhythm control versus rate control for atrial fibrillation and heart failure" 358 : 2667-2677, 2008

78 Chao TF, "Relationship of aging and incident comorbidities to stroke risk in patients with atrial fibrillation" 71 : 122-132, 2018

79 양필성, "Regional and Socioeconomic Inequality of Atrial Fibrillation with Regular Hospital Visit" 대한심장학회 48 (48): 635-636, 2018

80 Chan NC, "Real-world variability in dabigatran levels in patients with atrial fibrillation" 13 : 353-359, 2015

81 정보영, "Real-world Data and Recommended Dosage of Non-vitamin K Oral Anticoagulants for Korean Patients" 대한심장학회 47 (47): 833-841, 2017

82 Whitlock R, "Rationale and design of the Left Atrial Appendage Occlusion Study(LAAOS)III" 3 : 45-54, 2014

83 Al-Khatib SM, "Rate-and rhythm-control therapies in patients with atrial fibrillation : a systematic review" 160 : 760-773, 2014

84 de Denus S, "Rate vs rhythm control in patients with atrial fibrillation : a meta-analysis" 165 : 258-262, 2005

85 Opolski G, "Rate control vs rhythm control in patients with nonvalvular persistent atrial fibrillation : the results of the Polish How to Treat Chronic Atrial Fibrillation(HOT CAFE)Study" 126 : 476-486, 2004

86 Van Gelder IC, "Rate control in atrial fibrillation" 388 : 818-828, 2016

87 Kotecha D, "Rate and rhythm control have comparable effects on mortality and stroke in atrial fibrillation but better data are needed" 19 : 222-223, 2014

88 Thomas SP, "Rapid loading of sotalol or amiodarone for management of recent onset symptomatic atrial fibrillation : a randomized, digoxin-controlled trial" 147 : E3-, 2004

89 Schmidt-Lucke C, "Quality of anticoagulation with unfractionated heparin plus phenprocoumon for the prevention of thromboembolic complications in cardioversion for non-valvular atrial fibrillation. Sub-analysis from the Anticoagulation in Cardioversion using Enoxaparin (ACE) trial" 119 : 27-34, 2007

90 Holmes DR Jr, "Prospective randomized evaluation of the Watchman Left Atrial Appendage Closure device in patients with atrial fibrillation versus long-term warfarin therapy : the PREVAIL trial" 64 : 1-12, 2014

91 Reisinger J, "Prospective comparison of flecainide versus sotalol for immediate cardioversion of atrial fibrillation" 81 : 1450-1454, 1998

92 Krijthe BP, "Projections on the number of individuals with atrial fibrillation in the European Union, from 2000 to 2060" 34 : 2746-2751, 2013

93 Gorin L, "Prognosis and guideline-adherent antithrombotic treatment in patients with atrial fibrillation and atrial flutter : implications of undertreatment and overtreatment in real-life clinical practice; the Loire Valley Atrial Fibrillation Project" 140 : 911-917, 2011

94 Fox KA, "Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment" 32 : 2387-2394, 2011

95 Gibson CM, "Prevention of bleeding in patients with atrial fibrillation undergoing PCI" 375 : 2423-2434, 2016

96 Healey JS, "Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers : a meta-analysis" 45 : 1832-1839, 2005

97 Jibrini MB, "Prevention of atrial fibrillation by way of abrogation of the renin-angiotensin system : a systematic review and meta-analysis" 15 : 36-43, 2008

98 Schneider MP, "Prevention of atrial fibrillation by Renin-Angiotensin system inhibition a meta-analysis" 55 : 2299-2307, 2010

99 Choi HI, "Prevalence, management, and long-term(6-year)outcomes of atrial fibrillation among patients receiving drug-eluting coronary stents" 10 : 1075-1085, 2017

100 Kannel WB, "Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation : population-based estimates" 82 : 2N-9N, 1998

101 Go AS, "Prevalence of diagnosed atrial fibrillation in adults : national implications for rhythm management and stroke prevention : the AnTicoagulation and Risk Factors in Atrial Fibrillation(ATRIA)Study" 285 : 2370-2375, 2001

102 Davis RC, "Prevalence of atrial fibrillation in the general population and in high-risk groups : the ECHOES study" 14 : 1553-1559, 2012

103 Iguchi Y, "Prevalence of atrial fibrillation in community-dwelling Japanese aged 40 years or older in Japan : analysis of 41, 436 non-employee residents in Kurashiki-city" 72 : 909-913, 2008

104 이소령, "Prevalence of Nonnonevalvular Atrial Fibrillation Based on Geographical Distribution and Socioeconomic Status in the Entire Korean Population" 대한심장학회 48 (48): 622-634, 2018

105 De Simone A, "Pretreatment with verapamil in patients with persistent or chronic atrial fibrillation who underwent electrical cardioversion" 34 : 810-814, 1999

106 Thijs VN, "Predictors for atrial fibrillation detection after cryptogenic stroke : results from CRYSTAL AF" 86 : 261-269, 2016

107 Chatterjee S, "Pharmacologic rate versus rhythm-control strategies in atrial fibrillation : an updated comprehensive review and meta-analysis" 36 : 122-133, 2013

108 Douketis JD, "Perioperative bridging anticoagulation in patients with atrial fibrillation" 373 : 823-833, 2015

109 Hindricks G, "Performance of a new leadless implantable cardiac monitor in detecting and quantifying atrial fibrillation : results of the XPECT trial" 3 : 141-147, 2010

110 Reddy VY, "Percutaneous left atrial appendage closure vs warfarin for atrial fibrillation : a randomized clinical trial" 312 : 1988-1998, 2014

111 Reddy VY, "Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrial fibrillation: 2.3-year follow-up of the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients with Atrial Fibrillation) trial" 127 : 720-729, 2013

112 Holmes DR, "Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation : a randomised non-inferiority trial" 374 : 534-542, 2009

113 Lip GY, "Patient outcomes using the European label for dabigatran. A post-hoc analysis from the RE-LY database" 111 : 933-942, 2014

114 Alboni P, "Outpatient treatment of recent-onset atrial fibrillation with the"pill-in-the-pocket"approach" 351 : 2384-2391, 2004

115 Yu HT, "Outcomes of rate-control treatment in patients with atrial fibrillation and heart failure : a nationwide cohort study" 82 : 652-658, 2018

116 Siontis KC, "Outcomes associated with apixaban use in end-stage kidney disease patients with atrial fibrillation in the United States" 138 : 1519-1529, 2018

117 Piccini JP, "Outcomes after cardioversion and atrial fibrillation ablation in patients treated with rivaroxaban and warfarin in the ROCKET AF trial" 61 : 1998-2006, 2013

118 Khan IA, "Oral loading single dose flecainide for pharmacological cardioversion of recent-onset atrial fibrillation" 87 : 121-128, 2003

119 Chao TF, "Oral anticoagulation in very elderly patients with atrial fibrillation : a nationwide cohort study" 138 : 37-47, 2018

120 Gami AS, "Obstructive sleep apnea, obesity, and the risk of incident atrial fibrillation" 49 : 565-571, 2007

121 Wang TJ, "Obesity and the risk of new-onset atrial fibrillation" 292 : 2471-2477, 2004

122 Lip GY, "Non-vitamin K antagonist oral anticoagulants(NOACs)for stroke prevention in Asian patients with atrial fibrillation : time for a reappraisal" 180 : 246-254, 2015

123 Eckman MH, "Moving the tipping point : the decision to anticoagulate patients with atrial fibrillation" 4 : 14-21, 2011

124 Echt DS, "Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial" 324 : 781-788, 1991

125 Lau DH, "Modifiable risk factors and atrial fibrillation" 136 : 583-596, 2017

126 Guo Y, "Mobile health technology for atrial fibrillation management integrating decision support, education, and patient involvement: mAF App Trial" 130 : 1388-1396.e6, 2017

127 Freemantle N, "Mixed treatment comparison of dronedarone, amiodarone, sotalol, flecainide, and propafenone, for the management of atrial fibrillation" 13 : 329-345, 2011

128 Del-Carpio Munoz F, "Meta-analysis of renal function on the safety and efficacy of novel oral anticoagulants for atrial fibrillation" 117 : 69-75, 2016

129 Anand K, "Meta-analysis : inhibition of renin-angiotensin system prevents new-onset atrial fibrillation" 152 : 217-222, 2006

130 Hart RG, "Meta-analysis : antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation" 146 : 857-867, 2007

131 Darby AE, "Management of atrial fibrillation in patients with structural heart disease" 125 : 945-957, 2012

132 Chao TF, "Major bleeding and intracranial hemorrhage risk prediction in patients with atrial fibrillation : attention to modifiable bleeding risk factors or use of a bleeding risk stratification score? A nationwide cohort study" 254 : 157-161, 2018

133 Yap KB, "Low prevalence of atrial fibrillation in community-dwelling Chinese aged 55 years or older in Singapore : a population-based study" 41 : 94-98, 2008

134 Chao TF, "Lifetime risks, projected numbers, and adverse outcomes in Asian patients with atrial fibrillation : a report from the Taiwan nationwide AF cohort study" 153 : 453-466, 2018

135 Van Gelder IC, "Lenient versus strict rate control in patients with atrial fibrillation" 362 : 1363-1373, 2010

136 Kim TH, "Left ventricular diastolic dysfunction is associated with atrial remodeling and risk or presence of stroke in patients with paroxysmal atrial fibrillation" 68 : 104-109, 2016

137 Holmes DR Jr, "Left atrial appendage closure as an alternative to warfarin for stroke prevention in atrial fibrillation : a patient-level meta-analysis" 65 : 2614-2623, 2015

138 Lip GYH, "Joint European consensus document on the management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous cardiovascular interventions: a joint consensus document of the European Heart Rhythm Association (EHRA), European Society of Cardiology Working Group on Thrombosis, European Association of Percutaneous Cardiovascular Interventions (EAPCI), and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS), Latin America Heart Rhythm Society (LAHRS), and Cardiac Arrhythmia Society of Southern Africa (CASSA)" 2018

139 Siu CW, "Intravenous diltiazem is superior to intravenous amiodarone or digoxin for achieving ventricular rate control in patients with acute uncomplicated atrial fibrillation" 37 : 2174-2179, 2009

140 The Digitalis in Acute Atrial Fibrillation(DAAF)Trial Group, "Intravenous digoxin in acute atrial fibrillation. Results of a randomized, placebo-controlled multicentre trial in 239 patients" 18 : 649-654, 1997

141 Clemo HF, "Intravenous amiodarone for acute heart rate control in the critically ill patient with atrial tachyarrhythmias" 81 : 594-598, 1998

142 Nuño R, "Integrated care for chronic conditions : the contribution of the ICCC Framework" 105 : 55-64, 2012

143 Benjamin EJ, "Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study" 271 : 840-844, 1994

144 Kim D, "Increasing trends in hospital care burden of atrial fibrillation in Korea, 2006 through 2015" 2018

145 Køber L, "Increased mortality after dronedarone therapy for severe heart failure" 358 : 2678-2687, 2008

146 Chao TF, "Incident risk factors and major bleeding in patients with atrial fibrillation treated with oral anticoagulants : a comparison of baseline, follow-up and delta HAS-BLED scores with an approach focused on modifiable bleeding risk factors" 118 : 768-777, 2018

147 Gage BF, "Incidence of intracranial hemorrhage in patients with atrial fibrillation who are prone to fall" 118 : 612-617, 2005

148 Bodenheimer T, "Improving primary care for patients with chronic illness" 288 : 1775-1779, 2002

149 Kirchhof P, "Improving outcomes in patients with atrial fibrillation : rationale and design of the Early treatment of Atrial fibrillation for Stroke prevention Trial" 166 : 442-448, 2013

150 Proietti M, "Improved outcomes by integrated care of anticoagulated patients with atrial fibrillation using the simple ABC (Atrial Fibrillation Better Care) pathway" 2018

151 Boersma LV, "Implant success and safety of left atrial appendage closure with the WATCHMAN device : peri-procedural outcomes from the EWOLUTION registry" 37 : 2465-2474, 2016

152 Yu HY, "Impact of renal function on outcomes with edoxaban in real-world patients with atrial fibrillation : a nationwide cohort study" 49 : 2421-2429, 2018

153 Fatemi O, "Impact of intensive glycemic control on the incidence of atrial fibrillation and associated cardiovascular outcomes in patients with type 2 diabetes mellitus(from the Action to Control Cardiovascular Risk in Diabetes Study)" 114 : 1217-1222, 2014

154 Benjamin EJ, "Impact of atrial fibrillation on the risk of death : the Framingham Heart Study" 98 : 946-952, 1998

155 Kim D, "Ideal blood pressure in patients with atrial fibrillation" 72 : 1233-1245, 2018

156 Manolis AJ, "Hypertension and atrial fibrillation: diagnostic approach, prevention and treatment. Position paper of the Working Group ‘Hypertension Arrhythmias and Thrombosis’ of the European Society of Hypertension" 30 : 239-252, 2012

157 Friberg L, "High prevalence of atrial fibrillation among patients with ischemic stroke" 45 : 2599-2605, 2014

158 Guha K, "Heart failure epidemiology : European perspective" 9 : 123-127, 2013

159 Nieuwlaat R, "Guideline-adherent antithrombotic treatment is associated with improved outcomes compared with undertreatment in high-risk patients with atrial fibrillation" 153 : 1006-1012, 2007

160 Mazurek M, "Guideline-adherent antithrombotic treatment improves outcomes in patients with atrial fibrillation : insights from the community-based Darlington atrial fibrillation registry" 92 : 1203-1213, 2017

161 Perera KS, "Global survey of the frequency of atrial fibrillation-associated stroke : embolic stroke of undetermined source global registry" 47 : 2197-2202, 2016

162 Kirchhof P, "Giant T–U waves precede torsades de pointes in long QT syndrome : a systematic electrocardiographic analysis in patients with acquired and congenital QT prolongation" 54 : 143-149, 2009

163 Fang MC, "Gender differences in the risk of ischemic stroke and peripheral embolism in atrial fibrillation : the AnTicoagulation and Risk factors In Atrial fibrillation(ATRIA)study" 112 : 1687-1691, 2005

164 Reisinger J, "Flecainide versus ibutilide for immediate cardioversion of atrial fibrillation of recent onset" 25 : 1318-1324, 2004

165 Nielsen PB, "Female sex is a risk modifier rather than a risk factor for stroke in atrial fibrillation: should we use a CHA2DS2-VA score rather than CHA2DS2-VASc?" 137 : 832-840, 2018

166 Mikkelsen AP, "Female sex as a risk factor for stroke in atrial fibrillation : a nationwide cohort study" 10 : 1745-1751, 2012

167 Lakkireddy D, "Feasibility and safety of uninterrupted rivaroxaban for periprocedural anticoagulation in patients undergoing radiofrequency ablation for atrial fibrillation : results from a multicenter prospective registry" 63 : 982-988, 2014

168 Di Biase L, "Feasibility and safety of uninterrupted periprocedural apixaban administration in patients undergoing radiofrequency catheter ablation for atrial fibrillation : results from a multicenter study" 12 : 1162-1168, 2015

169 Vranckx P, "Evaluation of the safety and efficacy of an edoxaban-based antithrombotic regimen in patients with atrial fibrillation following successful percutaneous coronary intervention(PCI)with stent placement : Rationale and design of the ENTRUST-AF PCI trial" 196 : 105-112, 2018

170 Lee SR, "Evaluation of the association between diabetic retinopathy and the incidence of atrial fibrillation : a nationwide population-based study" 223 : 953-957, 2016

171 Li CH, "European Society of Cardiology guideline-adherent antithrombotic treatment and risk of mortality in Asian patients with atrial fibrillation" 6 : 30734-, 2016

172 Lip GY, "European Heart Rhythm Association/Heart Failure Association joint consensus document on arrhythmias in heart failure, endorsed by the Heart Rhythm Society and the Asia Pacific Heart Rhythm Society" 18 : 12-36, 2016

173 Kim MH, "Estimation of total incremental health care costs in patients with atrial fibrillation in the United States" 4 : 313-320, 2011

174 Platia EV, "Esmolol versus verapamil in the acute treatment of atrial fibrillation or atrial flutter" 63 : 925-929, 1989

175 Swedberg K, "Eplerenone and atrial fibrillation in mild systolic heart failure : results from the EMPHASIS-HF(Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure)study" 59 : 1598-1603, 2012

176 Schreck DM, "Emergency management of atrial fibrillation and flutter : intravenous diltiazem versus intravenous digoxin" 29 : 135-140, 1997

177 Schmidt M, "Eighteen-year trends in stroke mortality and the prognostic influence of comorbidity" 82 : 340-350, 2014

178 Kotecha D, "Efficacy of β blockers in patients with heart failure plus atrial fibrillation : an individual-patient data meta-analysis" 384 : 2235-2243, 2014

179 Steinberg JS, "Efficacy of oral diltiazem to control ventricular response in chronic atrial fibrillation at rest and during exercise" 9 : 405-411, 1987

180 Chun KJ, "Efficacy of dronedarone versus propafenone in the maintenance of sinus rhythm in patients with atrial fibrillation after electrical cardioversion" 36 : 1169-1175, 2014

181 Hohnloser SH, "Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation : insights from the ARISTOTLE trial" 33 : 2821-2830, 2012

182 Stambler BS, "Efficacy and safety of repeated intravenous doses of ibutilide for rapid conversion of atrial flutter or fibrillation. Ibutilide Repeat Dose Study Investigators" 94 : 1613-1621, 1996

183 Van Gelder IC, "Efficacy and safety of flecainide acetate in the maintenance of sinus rhythm after electrical cardioversion of chronic atrial fibrillation or atrial flutter" 64 : 1317-1321, 1989

184 Hijazi Z, "Efficacy and safety of dabigatran compared with warfarin in relation to baseline renal function in patients with atrial fibrillation : a RE-LY(Randomized Evaluation of Long-term Anticoagulation Therapy)trial analysis" 129 : 961-970, 2014

185 Flaker G, "Efficacy and safety of apixaban in patients after cardioversion for atrial fibrillation : insights from the ARISTOTLE trial(Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation)" 63 : 1082-1087, 2014

186 Halvorsen S, "Efficacy and safety of apixaban compared with warfarin according to age for stroke prevention in atrial fibrillation : observations from the ARISTOTLE trial" 35 : 1864-1872, 2014

187 Sharma M, "Efficacy and harms of direct oral anticoagulants in the elderly for stroke prevention in atrial fibrillation and secondary prevention of venous thromboembolism : systematic review and meta-analysis" 132 : 194-204, 2015

188 Bianconi L, "Effects of oral propafenone administration before electrical cardioversion of chronic atrial fibrillation : a placebo-controlled study" 28 : 700-706, 1996

189 Villani GQ, "Effects of diltiazem pretreatment on direct-current cardioversion in patients with persistent atrial fibrillation: a single-blind, randomized, controlled study" 140 : e12-, 2000

190 Letelier LM, "Effectiveness of amiodarone for conversion of atrial fibrillation to sinus rhythm : a meta-analysis" 163 : 777-785, 2003

191 Chan NY, "Effectiveness of a nongovernmental organization-led large-scale community atrial fibrillation screening program using the smartphone electrocardiogram : an observational cohort study" 15 : 1306-1311, 2018

192 Winkelmayer WC, "Effectiveness and safety of warfarin initiation in older hemodialysis patients with incident atrial fibrillation" 6 : 2662-2668, 2011

193 Lin YC, "Effectiveness and safety of standard-and low-dose rivaroxaban in Asians with atrial fibrillation" 72 : 477-485, 2018

194 Cha MJ, "Effectiveness and safety of non-vitamin K antagonist oral anticoagulants in Asian patients with atrial fibrillation" 48 : 3040-3048, 2017

195 Hohnloser SH, "Effect of dronedarone on cardiovascular events in atrial fibrillation" 360 : 668-678, 2009

196 Shi LZ, "Effect of catheter ablation versus antiarrhythmic drugs on atrial fibrillation : a meta-analysis of randomized controlled trials" 10 : 816-822, 2015

197 Giugliano RP, "Edoxaban versus warfarin in patients with atrial fibrillation" 369 : 2093-2104, 2013

198 Goette A, "Edoxaban versus enoxaparin-warfarin in patients undergoing cardioversion of atrial fibrillation (ENSURE-AF): a randomised, open-label, phase 3b trial" 388 : 1995-2003, 2016

199 Lee SR, "Edoxaban in Asian patients with atrial fibrillation : effectiveness and safety" 72 : 838-853, 2018

200 Schädlich PK, "Economic evaluation of enoxaparin for anticoagulation in early cardioversion of persisting nonvalvular atrial fibrillation : a statutory health insurance perspective from Germany" 7 : 199-217, 2007

201 Yoon M, "Dynamic changes of CHA2DS2-VASc score and the risk of ischaemic stroke in Asian patients with atrial fibrillation : a nationwide cohort study" 118 : 1296-1304, 2018

202 Van Gelder IC, "Duration of device-detected subclinical atrial fibrillation and occurrence of stroke in ASSERT" 38 : 1339-1344, 2017

203 Cannon CP, "Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation" 377 : 1513-1524, 2017

204 Connolly SJ, "Dronedarone in high-risk permanent atrial fibrillation" 365 : 2268-2276, 2011

205 Singh BN, "Dronedarone for maintenance of sinus rhythm in atrial fibrillation or flutter" 357 : 987-999, 2007

206 Atarashi H, "Double-blind placebo-controlled trial of aprindine and digoxin for the prevention of symptomatic atrial fibrillation" 66 : 553-556, 2002

207 Lee WC, "Direct treatment cost of atrial fibrillation in the elderly American population : a Medicare perspective" 11 : 281-298, 2008

208 Goldstein RE, "Diltiazem increases late-onset congestive heart failure in postinfarction patients with early reduction in ejection fraction. The Adverse Experience Committee; and the Multicenter Diltiazem Postinfarction Research Group" 83 : 52-60, 1991

209 Hwang JJ, "Diagnostic accuracy of transesophageal echocardiography for detecting left atrial thrombi in patients with rheumatic heart disease having undergone mitral valve operations" 72 : 677-681, 1993

210 Sposato LA, "Diagnosis of atrial fibrillation after stroke and transient ischaemic attack : a systematic review and meta-analysis" 14 : 377-387, 2015

211 Santini M, "Device-detected atrial tachyarrhythmias predict adverse outcome in real-world patients with implantable biventricular defibrillators" 57 : 167-172, 2011

212 Boriani G, "Device-detected atrial fibrillation and risk for stroke : an analysis of >10, 000 patients from the SOS AF project(Stroke preventiOn Strategies based on Atrial Fibrillation information from implanted devices)" 35 : 508-516, 2014

213 Ziolo MT, "Defining the role of oxidative stress in atrial fibrillation and diabetes" 26 : 223-225, 2015

214 Nagarakanti R, "Dabigatran versus warfarin in patients with atrial fibrillation : an analysis of patients undergoing cardioversion" 123 : 131-136, 2011

215 Connolly SJ, "Dabigatran versus warfarin in patients with atrial fibrillation" 361 : 1139-1151, 2009

216 Chugh SS, "Current burden of sudden cardiac death: multiple source surveillance versus retrospective death certificate-based review in a large U.S. community" 44 : 1268-1275, 2004

217 Aronsson M, "Cost-effectiveness of mass screening for untreated atrial fibrillation using intermittent ECG recording" 17 : 1023-1029, 2015

218 Stewart S, "Cost of an emerging epidemic : an economic analysis of atrial fibrillation in the UK" 90 : 286-292, 2004

219 Steensig K, "Coronary artery disease is independent risk factor for stroke among patients with atrial fibrillation" 2018

220 Ruff CT, "Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation : a meta-analysis of randomised trials" 383 : 955-962, 2014

221 Wilber DJ, "Comparison of antiarrhythmic drug therapy and radiofrequency catheter ablation in patients with paroxysmal atrial fibrillation : a randomized controlled trial" 303 : 333-340, 2010

222 최유정, "Comparison of Rhythm and Rate Control Strategies for Stroke Occurrence in a Prospective Cohort of Atrial Fibrillation Patients" 연세대학교의과대학 59 (59): 258-264, 2018

223 Kim DS, "Comparision of the efficacy of propafenone and flecainide in patients with atrial fibrillation" 27 : 860-866, 1997

224 Guo Y, "Comparing bleeding risk assessment focused on modifiable risk factors only versus validated bleeding risk scores in atrial fibrillation" 131 : 185-192, 2018

225 ACTIVE Writing Group of the ACTIVE Investigators, "Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events(ACTIVE W) : a randomised controlled trial" 367 : 1903-1912, 2006

226 Arya A, "Clinical implications of various follow up strategies after catheter ablation of atrial fibrillation" 30 : 458-462, 2007

227 Lee SS, "Clinical implication of an impaired fasting glucose and prehypertension related to new onset atrial fibrillation in a healthy Asian population without underlying disease : a nationwide cohort study in Korea" 38 : 2599-2607, 2017

228 Cho MY, "Clinical effectiveness and safety of standard-dose and low-dose non-vitamin K antagonist oral anticoagulants in patients with nonvalvular atrial fibrillation: a nationwide population-based cohort study" 2017

229 Yamashita Y, "Clinical characteristics and outcomes in extreme elderly(age ≥ 85 years)Japanese patients with atrial fibrillation : the Fushimi AF registry" 149 : 401-412, 2016

230 Adams HP Jr, "Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment" 24 : 35-41, 1993

231 Heeringa J, "Cigarette smoking and risk of atrial fibrillation : the Rotterdam Study" 156 : 1163-1169, 2008

232 Stock S, "Chronic care model strategies in the United States and Germany deliver patient-centered, high-quality diabetes care" 33 : 1540-1548, 2014

233 Mun HS, "Chronic amiodarone therapy impairs the function of the superior sinoatrial node in patients with atrial fibrillation" 77 : 2255-2263, 2013

234 Man-Son-Hing M, "Choosing antithrombotic therapy for elderly patients with atrial fibrillation who are at risk for falls" 159 : 677-685, 1999

235 Anselmino M, "Catheter ablation of atrial fibrillation in patients with left ventricular systolic dysfunction : a systematic review and meta-analysis" 7 : 1011-1018, 2014

236 Roh SY, "Catheter ablation of atrial fibrillation in patients with chronic lung disease" 4 : 815-822, 2011

237 Marrouche NF, "Catheter ablation for atrial fibrillation with heart failure" 378 : 417-427, 2018

238 신동금, "Cardiovascular Events of Electrical Cardioversion Under Optimal Anticoagulation in Atrial Fibrillation: The Multicenter Analysis" 연세대학교의과대학 56 (56): 1552-1558, 2015

239 Kim TH, "CHA2DS2-VASc score(congestive heart failure, hypertension, age ≥75 [doubled], diabetes mellitus, prior stroke or transient ischemic attack [doubled], vascular disease, age 65–74, female)for stroke in Asian patients with atrial fibrillation : a Korean nationwide sample cohort study" 48 : 1524-1530, 2017

240 Kim TH, "CHA2DS2-VASc score for identifying truly low-risk atrial fibrillation for stroke : a Korean nationwide cohort study" 48 : 2984-2990, 2017

241 Douketis JD, "Bridging anticoagulation in patients with atrial fibrillation" 374 : 93-94, 2016

242 Zulkifly H, "Bleeding risk scores in atrial fibrillation and venous thromboembolism" 120 : 1139-1145, 2017

243 Lip GY, "Bleeding risk assessment in atrial fibrillation : observations on the use and misuse of bleeding risk scores" 14 : 1711-1714, 2016

244 Rizzo MR, "Autonomic dysfunction is associated with brief episodes of atrial fibrillation in type 2 diabetes" 29 : 88-92, 2015

245 Glotzer TV, "Atrial high rate episodes detected by pacemaker diagnostics predict death and stroke : report of the Atrial Diagnostics Ancillary Study of the MOde Selection Trial(MOST)" 107 : 1614-1619, 2003

246 Gladstone DJ, "Atrial fibrillation in patients with cryptogenic stroke" 370 : 2467-2477, 2014

247 Wizemann V, "Atrial fibrillation in hemodialysis patients : clinical features and associations with anticoagulant therapy" 77 : 1098-1106, 2010

248 Boriani G, "Asymptomatic atrial fibrillation: clinical correlates, management, and outcomes in the EORP-AF Pilot General Registry" 128 : 509-518.e2, 2015

249 Baek YS, "Associations of abdominal obesity and new-onset atrial fibrillation in the general population" 6 : 6-, 2017

250 Kong KA, "Associations between body mass index and mortality or cardiovascular events in a general Korean population" 12 : e0185024-, 2017

251 Friberg L, "Assessment of female sex as a risk factor in atrial fibrillation in Sweden: nationwide retrospective cohort study" 344 : e3522-, 2012

252 Halcox JP, "Assessment of Remote Heart Rhythm Sampling Using the AliveCor Heart Monitor to Screen for Atrial Fibrillation : the REHEARSE-AF Study" 136 : 1784-1794, 2017

253 Coyne KS, "Assessing the direct costs of treating nonvalvular atrial fibrillation in the United States" 9 : 348-356, 2006

254 Esteve-Pastor MA, "Assessing bleeding risk in atrial fibrillation patients: comparing a bleeding risk score based only on modifiable bleeding risk factors against the HAS-BLED score. The AMADEUS trial" 117 : 2261-2266, 2017

255 Allan V, "Are cardiovascular risk factors also associated with the incidence of atrial fibrillation? A systematic review and field synopsis of 23 factors in 32 population-based cohorts of 20 million participants" 117 : 837-850, 2017

256 Granger CB, "Apixaban versus warfarin in patients with atrial fibrillation" 365 : 981-992, 2011

257 Kirchhof P, "Apixaban in patients at risk of stroke undergoing atrial fibrillation ablation" 39 : 2942-2955, 2018

258 Ezekowitz MD, "Apixaban compared to heparin/vitamin K antagonist in patients with atrial fibrillation scheduled for cardioversion : the EMANATE trial" 39 : 2959-2971, 2018

259 Lip GY, "Antithrombotic therapy for atrial fibrillation: CHEST guideline and expert panel report" 154 (154): 2018

260 Ancedy Y, "Antithrombotic management in patients with atrial fibrillation undergoing coronary stent implantation : what is the impact of guideline adherence?" 203 : 987-994, 2016

261 Lamberts M, "Antiplatelet therapy for stable coronary artery disease in atrial fibrillation patients taking an oral anticoagulant : a nationwide cohort study" 129 : 1577-1585, 2014

262 Marott SC, "Antihypertensive treatment and risk of atrial fibrillation : a nationwide study" 35 : 1205-1214, 2014

263 Lafuente-Lafuente C, "Antiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fibrillation" 28 (28): CD005049-, 2015

264 Kirchhof P, "Anterior-posterior versus anterior-lateral electrode positions for external cardioversion of atrial fibrillation : a randomised trial" 360 : 1275-1279, 2002

265 Wachtell K, "Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol : the Losartan Intervention For End Point Reduction in Hypertension(LIFE)study" 45 : 712-719, 2005

266 Lopes RD, "An open-Label, 2 × 2 factorial, randomized controlled trial to evaluate the safety of apixaban vs. vitamin K antagonist and aspirin vs. placebo in patients with atrial fibrillation and acute coronary syndrome and/or percutaneous coronary intervention : rationale and design of the AUGUSTUS trial" 200 : 17-23, 2018

267 Hendriks JM, "An integrated chronic care program for patients with atrial fibrillation : study protocol and methodology for an ongoing prospective randomised controlled trial" 47 : 1310-1316, 2010

268 Singh BN, "Amiodarone versus sotalol for atrial fibrillation" 352 : 1861-1872, 2005

269 Chevalier P, "Amiodarone versus placebo and class Ic drugs for cardioversion of recent-onset atrial fibrillation : a meta-analysis" 41 : 255-262, 2003

270 Delle Karth G, "Amiodarone versus diltiazem for rate control in critically ill patients with atrial tachyarrhythmias" 29 : 1149-1153, 2001

271 Roy D, "Amiodarone to prevent recurrence of atrial fibrillation" 342 : 913-920, 2000

272 Singh SN, "Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia. Survival Trial of Antiarrhythmic Therapy in Congestive Heart Failure" 333 : 77-82, 1995

273 Khan IA, "Amiodarone for pharmacological cardioversion of recent-onset atrial fibrillation" 89 : 239-248, 2003

274 Conen D, "Alcohol consumption and risk of incident atrial fibrillation in women" 300 : 2489-2496, 2008

275 Kim TH, "Age threshold for ischemic stroke risk in atrial fibrillation" 49 : 1872-1879, 2018

276 Chao TF, "Age threshold for increased stroke risk among patients with atrial fibrillation : a nationwide cohort study from Taiwan" 66 : 1339-1347, 2015

277 Proietti M, "Adherence to antithrombotic therapy guidelines improves mortality among elderly patients with atrial fibrillation : insights from the REPOSI study" 105 : 912-920, 2016

278 Manning WJ, "Accuracy of transesophageal echocardiography for identifying left atrial thrombi. A prospective, intraoperative study" 123 : 817-822, 1995

279 Casu G, "ANMCO/AIAC/SICI-GISE/SIC/SICCH consensus document: percutaneous occlusion of the left atrial appendage in non-valvular atrial fibrillation patients: indications, patient selection, staff skills, organisation, and training" 19 : D333-D353, 2017

280 January CT, "AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society" 64 : e1-e76, 2014

281 Kirchhof P, "A trial of self-adhesive patch electrodes and hand-held paddle electrodes for external cardioversion of atrial fibrillation(MOBIPAPA)" 26 : 1292-1297, 2005

282 Li YG, "A simple clinical risk score (C2HEST) for predicting incident atrial fibrillation in Asian subjects: derivation in 471,446 Chinese subjects, with internal validation and external application in 451,199 Korean subjects" 2018

283 Wang TJ, "A risk score for predicting stroke or death in individuals with new-onset atrial fibrillation in the community : the Framingham Heart Study" 290 : 1049-1056, 2003

284 Tisdale JE, "A randomized, double-blind comparison of intravenous diltiazem and digoxin for atrial fibrillation after coronary artery bypass surgery" 135 : 739-747, 1998

285 Vijayalakshmi K, "A randomized trial of prophylactic antiarrhythmic agents (amiodarone and sotalol) in patients with atrial fibrillation for whom direct current cardioversion is planned" 151 : 863.e1-863.e6, 2006

286 Channer KS, "A randomized placebo-controlled trial of pre-treatment and short-or long-term maintenance therapy with amiodarone supporting DC cardioversion for persistent atrial fibrillation" 25 : 144-150, 2004

287 Camm AJ, "A randomized active-controlled study comparing the efficacy and safety of vernakalant to amiodarone in recent-onset atrial fibrillation" 57 : 313-321, 2011

288 Hobbs FD, "A randomised controlled trial and cost-effectiveness study of systematic screening (targeted and total population screening) versus routine practice for the detection of atrial fibrillation in people aged 65 and over" 9 : iii-iv, 2005

289 Goldschlager N, "A practical guide for clinicians who treat patients with amiodarone : 2007" 4 : 1250-1259, 2007

290 Stewart S, "A population-based study of the long-term risks associated with atrial fibrillation : 20-year follow-up of the Renfrew/Paisley study" 113 : 359-364, 2002

291 Ellenbogen KA, "A placebo-controlled trial of continuous intravenous diltiazem infusion for 24-hour heart rate control during atrial fibrillation and atrial flutter : a multicenter study" 18 : 891-897, 1991

292 Levin LA, "A cost-effectiveness analysis of screening for silent atrial fibrillation after ischaemic stroke" 17 : 207-214, 2015

293 Van Gelder IC, "A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation" 347 : 1834-1840, 2002

294 Wyse DG, "A comparison of rate control and rhythm control in patients with atrial fibrillation" 347 : 1825-1833, 2002

295 Potpara TS, "A comparison of clinical characteristics and long-term prognosis in asymptomatic and symptomatic patients with first-diagnosed atrial fibrillation : the Belgrade Atrial Fibrillation Study" 168 : 4744-4749, 2013

296 Leon MB, "A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting" 339 : 1665-1671, 1998

297 김형수, "A Prospective Survey of Atrial Fibrillation Management for Real-world Guideline Adherence: COmparison study of Drugs for symptom control and complication prEvention of Atrial Fibrillation (CODE-AF) Registry" 대한심장학회 47 (47): 877-887, 2017

298 Schnabel RB, "50 year trends in atrial fibrillation prevalence, incidence, risk factors, and mortality in the Framingham Heart Study : a cohort study" 386 : 154-162, 2015

299 Schmidt M, "30-year nationwide trends in incidence of atrial fibrillation in Denmark and associated 5-year risk of heart failure, stroke, and death" 225 : 30-36, 2016

300 Chiang CE, "2017 consensus of the Asia Pacific Heart Rhythm Society on stroke prevention in atrial fibrillation" 33 : 345-367, 2017

301 Calkins H, "2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation" 14 : e275-e444, 2017

302 Valgimigli M, "2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS : The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology(ESC)and of the European Association for Cardio-Thoracic Surgery(EACTS)" 39 : 213-260, 2018

303 Kirchhof P, "2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS" 37 : 2893-2962, 2016

304 January CT, "2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society" 130 : e199-e267, 2014

305 Chiang CE, "2010 guidelines of the Taiwan Society of Cardiology for the management of hypertension" 109 : 740-773, 2010

306 Kim D, "10-year nationwide trends of the incidence, prevalence, and adverse outcomes of non-valvular atrial fibrillation nationwide health insurance data covering the entire Korean population" 202 : 20-26, 2018